Publications by authors named "B Kleinhappl"
B-cell depleting therapies result in diminished humoral immunity following vaccination against COVID-19, but our understanding on the impact on cellular immune responses is limited. Here, we performed a detailed analysis of cellular immunity following mRNA vaccination in patients receiving B-cell depleting therapy using ELISpot assay and flow cytometry. Anti-SARS-CoV-2 spike receptor-binding domain antibody assays were performed to elucidate B-cell responses.
View Article and Find Full Text PDFSevere acute respiratory syndrome coronavirus 2 spike antibody level decline is more pronounced after the second vaccination, but response to the third vaccination is similar in people with type 1 and type 2 diabetes compared with healthy controls: The prospective COVAC-DM cohort study.
Diabetes Obes Metab
January 2023
Article Synopsis
- Individuals with ABO type O have natural antibodies (anti-A and anti-B) that may help protect against SARS-CoV-2 infection, as they are less frequently found among infected patients compared to healthy people.
- The study compared levels of these antibodies and subclasses (IgM, IgG, IgA) in the serum and saliva of Caucasian individuals who had mild COVID-19 with those who had never been infected.
- Results showed that convalescent individuals had lower serum levels of anti-A/anti-B antibodies compared to controls, but no differences in saliva, suggesting that high serum levels could offer some protection against the virus.
Measuring SARS-CoV-2 neutralizing antibodies after vaccination or natural infection remains a priority in the ongoing COVID-19 pandemic to determine immunity, especially against newly emerging variants. The gold standard for assessing antibody-mediated immunity against SARS-CoV-2 are cell-based live virus neutralization assays. These assays usually take several days, thereby limiting test capacities and the availability of rapid results.
View Article and Find Full Text PDFAims: To investigate the seroconversion following first and second COVID-19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and to analyse the response in comparison to individuals without diabetes.
Materials And Methods: This prospective, multicentre cohort study analysed people with type 1 and type 2 diabetes and a glycated haemoglobin level ≤58 mmol/mol (7.5%) or >58 mmol/mol (7.